Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Absence of adverse effects of tiotropium/ olodaterol compared with the monocomponents on long-term heart rate and blood pressure in patients with moderate-to-very-severe COPD
Authors:Andreas, Stefan (Author)
Mcgarvey, Lorcan (Author)
Bothner, Ulrich (Author)
Trampisch, Matthias (Author)
De La Hoz, Alberto (Author)
Fležar, Matjaž (Author)
Buhl, Roland (Author)
Alter, Peter (Author)
Language:English
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Introduction: Long-acting [beta]2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are established maintenance bronchodilator treatments for chronic obstructive pulmonary disease (COPD) with the potential to increase heart rate (HR) and impact blood pressure (BP). While previous studies indicate that HR and BP are not negatively influenced by tiotropium or olodaterol monotherapy, the effect of tiotropium/olodaterol has not been evaluated. We report a post hoc analysis of the effect of dual bronchodilation with tiotropium/olodaterol versus monocomponents on HR and BP in patients with moderate-to-very-severe COPD included in the large TONADO© study. Methods: The TONADO© trials (1237.5 [NCT01431274] and 1237.6 [NCT01431287]) were two replicate, randomized, double-blind, parallel-group, 52-week, Phase III trials that compared tiotropium/olodaterol (5/5 [micro]g and 2.5/5 [micro]g) with tiotropium (5 [micro]g and 2.5 [micro]g) and olodaterol (5 [micro]g) in patients with moderate-to-very-severe COPD. Patients with cardiovascular comorbidities were included. Changes in HR and systolic/diastolic BP were measured before and after dosing with the study medication at each visit (baseline, Week 12, Week 24 and Week 52). Results: Overall, 3,100 patients were included in this analysis. Over 52 weeks, small changes from baseline in mean HR (<2 beats per minute [bpm]) and small changes from pre- to post-dose (<1 bpm) were evident at different time points. There was a non-significant increase from baseline in mean diastolic and systolic BP (<2 mmHg) observed over 52 weeks of treatment. The short-term (1 hour pre- to 1 hour post-dose) mean changes in systolic and diastolic BP over 52 weeks in the tiotropium/olodaterol 5/5 [micro]g group were comparable with those observed for the monocomponents at all time points. Conclusion: There were no differences in HR or BP among patients on tiotropium/olodaterol when compared with monocomponents. This supports the already demonstrated cardiovascular safety profile of tiotropium/olodaterol as long-acting maintenance bronchodilator treatment for COPD, including patients with cardiovascular comorbidities.
Keywords:pulmonary disease, chronic obstructive -- drug therapy, heart rate, blood pressure, tiotropium, olodaterol
Year of publishing:2020
Publisher:Dove Medical Press
Source:Nova Zelandija
COBISS_ID:28042755 Link is opened in a new window
UDC:616.2
ISSN on article:1178-2005
OceCobissID:512411449 Link is opened in a new window
DOI:10.2147/COPD.S246348 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Soavtor iz Slovenije: Matjaž Fležar; Opis vira z dne 11. 9. 2020;
Views:275
Downloads:171
Files:URL URL - Presentation file, visit https://www.dovepress.com/getfile.php?fileID=60472
 
Journal:Int. j. COPD
Dove Medical Press
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© 2020 Andreas et al.
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY-NC 3.0, Creative Commons Attribution Non-Commercial 3.0
Link:http://creativecommons.org/licenses/by-nc/3.0/
Description:You are free to reproduce and redistribute the material in any medium or format. You are free to remix, transform, and build upon the material. You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Licensing start date:12.06.2020

Back